• UK continues to support the group • Rebalancing expectations lead to -3% on '23e estimates • We lo...
Redeye leaves a comment following Lipum’s announcement of the preliminary outcome of the rights issu...
Q-linea is in a transition period after the break with Thermo Fisher and in Q2 there are two deliver...
Redeye states that the Q2 report was decent - far from the catastrophe that the recent share-price d...
Cibus' Q2 2023 income from property management (IFPM) was in line with our expectations but slightly...
Redeye retains its positive view of Avensia despite a soft Q2, with sales and EBIT below our expecta...
Kvartalet i korthet: Omsättningen uppgick till 8,8 mkr (9,6) och rörelseresultatet uppgick till -11,...
EBITDA of SEK 69m, below ABGSCe due to project timingOwn production better, we raise '23e EBITDA by ...
• Q2 report due on Friday, 11 August • Organic slowdown and FX headwinds on margins • Trading at 11x...
• Q2 report due on Thursday, 17 August • Non-woven in high gear, FW likely to struggle • NWC release...
Redeye retains its positive view of Avensia despite a softer Q2 than expected.
IRLAB Therapeutics has provided an update on its ongoing Phase IIb clinical trial for pirepemat, whi...
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Amid 1) a hiccup in its turnaround; 2) a shift in the investor base; and 3) low liquidity in the sha...
• Net sales SEK 456m, -2% vs ABGSCe SEK 464m • EBITA SEK 58m, -4% vs ABGSCe SEK 60m • Share is +31% ...
Cibus posted Q2 net operating income of EUR 28.1m, up 11% y/y on the back of acquisitions and in lin...
Carasent’s Q2 2023 report contained no big surprises.
Vaisala revised its net sales guidance and reduced its EBIT expectations for 2023.
Redeye returns with an update on Stille following its Q2 2023 report.
• Better-than-expected Q2 report, mainly driven by Public DK • We raise our EBIT estimates on lower ...
